Bausch Health Companies Inc.
BHC
Positions held
Your positionsBHC isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Bausch Health Companies Inc. is well-positioned in the specialty and generic drug market, leveraging its diverse product portfolio to capture a larger market share.
- Revenue increased by 13% compared to the prior quarter, reaching $2.9 billion.
- Operating margin expanded to 27.2%, indicating improved operational efficiency.
- Despite its growth, Bausch Health faces challenges with a negative profit margin of -10.1%, which may deter potential investors.
- Net income was -$1.4 billion in Q1 2026, reflecting ongoing financial struggles.
- The company's price-to-book ratio stands at -1.27, suggesting potential overvaluation concerns.
Fundamentals
| Market cap | $2.26B | Enterprise value | $22.18B | Trailing P/E | — | Forward P/E | 1.44 |
| PEG | 0.01 | Price / book | -1.28 | Beta | 0.37 | Dividend yield | 0.00% |
| Revenue growth | 12.7% | Earnings growth | 70.4% | Gross margin | 71.8% | Operating margin | 27.2% |
| Profit margin | -10.1% | ROE | — | ROA | 6.6% | Debt / equity | — |
| Current ratio | 1.44 | Free cash flow | $1.43B | Analyst recommendation | hold | Mean target | $7.50 |
| 52w high | $8.00 | 52w low | $4.33 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.5B | $2.8B | $2.7B | $2.5B | — |
| Op margin | 27.2% | 20.6% | 29.6% | 23.7% | 18.1% | — |
| Net income | $258M | -$1.4B | -$112M | $179M | $148M | — |
| Gross margin | 72.9% | 70.8% | 71.5% | 72.0% | 69.8% | — |
| Gross profit | $2.1B | $1.8B | $2.0B | $1.9B | $1.8B | — |
| Operating income | $775M | $521M | $829M | $636M | $457M | — |
- Revenue +13% vs prior quarter ($2.9B vs $2.5B).
- Gross margin 72.9% (was 70.8% prior quarter).
- Operating margin expanded to 27.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.3B | $9.6B | $8.8B | $8.1B | — |
| Op margin | 21.3% | 19.3% | 18.3% | 17.1% | — |
| Net income | $157M | -$46.0M | -$592M | -$225M | — |
| Gross margin | 70.7% | 71.1% | 70.8% | 70.9% | — |
| Gross profit | $7.3B | $6.8B | $6.2B | $5.8B | — |
| Operating income | $2.2B | $1.9B | $1.6B | $1.4B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
2026-10-06 · Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
2026-10-05 · The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
2026-10-02 · 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
2026-09-30 · Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
2026-09-28 · Zacks Value Investor Highlights: FOXF, BHC and QNST
2026-09-24 · Screening for Hidden Gem Stocks Under $20
2026-09-22 · Best Value Stocks to Buy for September 22nd
2026-09-16 · Bausch Health (BHC) Expands Probiotic Skincare Bet To Six New Markets
2026-09-14 · 4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
2026-09-08 · Bausch Health Expands Collaboration With Belgian Dermatology Company Yun
2026-09-08 · Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
Price (daily)
Full chart · RSI · MACD · patterns